Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.
Internet Explorer 10, Firefox, Chrome, or Safari.
All media inquiries can be directed to mediarelations@cysticfibrosis.ca or by calling 1-800-378-2233.
Cystic Fibrosis Canada calls on public and private payers to immediately fund Trikafta for all who can benefit.
Read MoreSix Research Grants, an Early Career Investigator Award and three Research Fellowships focus on CF Community’s Health Needs
Read MoreCystic Fibrosis Canada asks participants to go #FurtherTogether for Canadians with cystic fibrosis
Read MoreCystic Fibrosis Canada calls on provinces, territories, and private insurers to immediately to fund Trikafta for all who can benefit
Read MoreTORONTO (March 10, 2022) – Cystic Fibrosis Canada today announces that it has achieved reaccreditation under Imagine Canada’s Standards Program, being an accredited member of the Standard Program since October 1st, 2015. Accredited organizations are required to complete full reaccreditation on a five-year basis. With this achievement, Cystic Fibrosis Canada remains a distinguished member of the ever-growing community of 250+ nonprofit organizations dedicated to operational excellence.
Read MoreTORONTO 4 March, 2022 - The Quebec Court of Appeal has issued a much-anticipated decision in the court case brought forward by a number of pharmaceutical companies, led by Merck Canada, Inc, and on which Cystic Fibrosis Canada intervened. In a unanimous decision the three judges struck down two key proposed changes to the Patented Medicine Prices Review Board (PMPRB) guidelines, opening the way to improved access to medicines for patients living with cystic fibrosis.
Read MoreNew CF Trends Report finds a disease in transition
Read MoreCystic Fibrosis Canada launches sixth annual holiday campaign to lengthen and improve lives
Read More
